EHA Library - The official digital education library of European Hematology Association (EHA)

THE PREDICTIVE VALUE OF PLATELET SPECIFIC ANTIBODIES FOR THE FIRST-LINE TREATMENT EFFECT IN NEWLY DIAGNOSED PEDIATRIC ITP
Author(s):
Shuyue Dong
Affiliations:
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,Chine;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,Cina;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,Kina
EHA Library. dong S. 06/10/22; 359149; PB2297
Shuyue dong
Shuyue dong
Contributions
Abstract
References

Abstract: PB2297

Type: Publication Only

Session title: Platelet disorders

Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction. 

Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.

Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.

Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.

Conclusion
Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.

Keyword(s): Antibody, Immune thrombocytopenia (ITP), Treatment

Abstract: PB2297

Type: Publication Only

Session title: Platelet disorders

Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction. 

Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.

Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.

Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.

Conclusion
Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.

Keyword(s): Antibody, Immune thrombocytopenia (ITP), Treatment

Abstract: PB2297

Type: Publication Only

Session title: Platelet disorders

Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction. 

Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.

Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.

Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.

Conclusion
Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.

Keyword(s): Antibody, Immune thrombocytopenia (ITP), Treatment

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies